Keryx Biopharmaceuticals — FY2015 Earnings Presentation
23 slides from Keryx Biopharmaceuticals's earnings presentation, Feb 25, 2016
Slide 1: Fourth Quarter and Year End 2015 Financial Results
Fourth Quarter and Year End 2015 Financial Results February 25, 2016 Keryx Biopharmaceuticals, Inc. Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Important factors may cause our actual results to differ
Slide 3: Fourth Quarter and Full Year 2015 Financial Results – Agenda
Fourth Quarter and Full Year 2015 Financial Results – Agenda Topic Speaker Introduction Amy Sullivan, VP, Corporate Development Business Highlights Greg Madison, Chief Executive Officer 4Q 2015 Results & 2016 Guidance Scott Holmes, Chief Financial Officer Auryxia Commercial Overview Abe Ceesay, VP,
Slide 4: Building a Leading Renal Company
Building a Leading Renal Company Today Near Term Future One medicine, multiple indications Multi-product company focused on improving the lives of people with renal disease One medicine, one indication * Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dia
Slide 5: Business Highlights
Business Highlights Ended 2015 with solid fundamentals Expanded sales force to drive depth and breadth of prescribing Secured reimbursement coverage for majority of phosphate binder patients Received EU approval of ferric citrate for the control of hyperphosphatemia in patients with all stages of CK
Slide 6: Current Auryxia (Ferric Citrate) Indication
Current Auryxia™ (Ferric Citrate) Indication Phosphate Management Non-calcium, non-chewable, absorbable, iron-based phosphate binder Pharmacodynamic properties have shown to increase serum iron parameters, including TSAT and ferritin Established safety profile Most common AEs GI-related Recommended
Slide 7: A Potential New Treatment for Iron Deficiency Anemia
A Potential New Treatment for Iron Deficiency Anemia Anemia Management In January, completed pivotal phase 3 trial evaluating ferric citrate for treatment of IDA in pre-dialysis stages 3-5 CKD Plan to provide top-line safety and efficacy results in early 2Q 2016 If successful, plan to: submit regula
Slide 8: A Potential New Treatment Category for CKD
A Potential New Treatment Category for CKD Phosphate Management Anemia Management * Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dialysis; **Keryx is currently conducting a phase 3 trial evaluating ferric citrate for use in pre-dialysis CKD patients as
Slide 9: Building a Foundation for Long-Term Growth
Building a Foundation for Long-Term Growth SOLID FUNDAMENTALS ESTABLISHED 2015 2017 POTENTIAL IDA APPROVAL 2016 DRIVE DIALYSIS ADOPTION AURYXIA: A NEW TREATMENT CATEGORY Leverage sales force expansion Increase utilization Increase breadth & depth of prescribing Generate further data to support diffe
Slide 10: Financial Highlights
Financial Highlights Scott Holmes Chief Financial Officer
Slide 11: Fourth Quarter and Full Year 2015 Financial Highlights
Fourth Quarter and Full Year 2015 Financial Highlights ($ in thousands) Three Months Ended December 31, 2015 (unaudited) Full Year December 31, 2015 (unaudited) Auryxia Net U.S. Product Sales $4,770 $10,141 License Revenue $1,013 $3,539 Total Revenue $5,783 $13,680 COGS $1,075 $4,520 SG&A Expense $2
Slide 12: Selected 2015 Financial Results and 2016 Guidance
Selected 2015 Financial Results and 2016 Guidance $ in millions FY 2015 Actuals FY 2016 Guidance Auryxia Net U.S. Product Sales* $10.1MM $31MM - $34MM Cash Operating Expenses $99.7MM* $87MM - $92MM** Notes: * 2015 Cash Operating Expense amount excludes a total of $18.4M in non-cash expenses, compris
Slide 13: Commercial Progress
Commercial Progress Abe Ceesay VP, Sales, Marketing and Operations
Slide 14: Prescription Volume Increased ~46% from 3Q to 4Q 2015
Source: IMS NPA, DaVita and Fresenius Prescription Volume Increased ~46% from 3Q to 4Q 2015 ~7,850 Auryxia prescriptions in 4Q 2015 43% of Auryxia prescriptions in 4Q 2015 not captured by IMS Non-IMS reporting channel prescription volume increased ~60% from 3Q to 4Q Volume growth driven by increased
Slide 15: Key Factors That Drove Auryxia Adoption and Growth in 4Q'15
Key Factors That Drove Auryxia™ Adoption and Growth in 4Q’15 Refined commercial message: New dialysis patients 30% - 40% of ESRD patients with serum phosphorus levels above 5.5 mg/dL Increased new writers: Cumulative targets who have written an Rx grew >25% from 3Q to 4Q Focused sales effort: Direct
Slide 16: Sales Force Expansion Supports Continued Auryxia Adoption in Dialysis
Represents ~85% of Rxs Sales Force Expansion Supports Continued Auryxia Adoption in Dialysis ~5,000 Prescribers Sales Force Expansion Complete and New Reps Trained Dialysis Care Team 95 Sales Representatives Total Market Coverage 11 Regional Managers
Slide 17: Solid Fundamentals to Support Future Dialysis Growth
Solid Fundamentals to Support Future Dialysis Growth Physician Payer Patient Increased breadth and depth of adoption Increased field base team to 95, with 11 district managers Majority of phosphate binder patients have unrestricted access >70% of claims paid at the pharmacy ~74% of co-pays <$10 Pati
Slide 18: Label Expansion Efforts
Label Expansion Efforts John Neylan, M.D. Chief Medical Officer
Slide 19: Treating Iron Deficiency Anemia in Pre-Dialysis: A Practice-Changing Opportunity
The Potential to Treat Iron Deficiency Anemia in Pre-Dialysis Represents a Practice-Changing Opportunity Sources: http://www.kidney.org/kidneydisease; U.S. Renal Data System, USRDS 2015 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Ins
Slide 20: Phase 3 Iron Deficiency Anemia Label Expansion Study
Phase 3 Iron Deficiency Anemia Label Expansion Study Primary endpoint: % of patients achieve a 1 g/dL or greater increase in hemoglobin during 16-week randomization period Two-month safety follow up period, for total of 24 weeks Screening Randomization 1:1 2 Week 16 Week Randomized, Double-Blind Pla
Slide 21: Auryxia Well Positioned for Future Market Leadership
Auryxia Well Positioned for Future Market Leadership CKD** ESRD* Stage 3 Stage 4 Iron Deficient Value A Two-Staged Growth Strategy for Auryxia Uncontrolled Phosphorus * Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dialysis; **Keryx is currently conduct
Slide 22: Priorities for the Future
Priorities for the Future Drive Auryxia’s path to success in dialysis: Increase awareness Drive breadth and depth of prescribing Address the unmet need in pre-dialysis CKD patients with iron deficiency anemia** Expand global reach of ferric citrate * Auryxia is currently indicated for the control of
Slide 23: Fourth Quarter and Year End 2015 Financial Results
Fourth Quarter and Year End 2015 Financial Results February 25, 2016 Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals — FY2015 Earnings Presentation on 6ix